Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-411-2 | CAS number: 95-33-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Referenceopen allclose all
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 981
- Report date:
- 1981
- Reference Type:
- publication
- Title:
- Teratology studies on benzothiazolesulfenamides
- Author:
- Levinskas, G.J.
- Year:
- 1 982
- Bibliographic source:
- The Toxicologist 2, 73
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Principles of method if other than guideline:
- Groups of 25 pregnant females were treated by gavage with CBS at dose levels of 100, 300, 500, and 900 mg/kg bw and day during gestation day 6 to 15. Cesarean sections were performed on all surviving dams on gestation day 20.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- N-cyclohexylbenzothiazole-2-sulfenamide
- EC Number:
- 202-411-2
- EC Name:
- N-cyclohexylbenzothiazole-2-sulfenamide
- Cas Number:
- 95-33-0
- Molecular formula:
- C13H16N2S2
- IUPAC Name:
- N-(1,3-benzothiazol-2-ylsulfanyl)cyclohexanamine
- Test material form:
- solid: particulate/powder
- Remarks:
- Beige
- Details on test material:
- Test substance: Santocure CBS
- Analytical purity: 96.2 %
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Charles River COBS CD
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on mating procedure:
- M/F ratio per cage: 1:1
- Duration of treatment / exposure:
- 6th to 15th day of pregnancy
- Frequency of treatment:
- Daily
- Duration of test:
- GD 20 (scheduled sacrifice)
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Remarks:
- Control
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- Dose / conc.:
- 500 mg/kg bw/day
- Dose / conc.:
- 900 mg/kg bw/day
- No. of animals per sex per dose:
- 25 females per dose
- Control animals:
- yes
- Details on study design:
- Sex: female
Examinations
- Maternal examinations:
- Appearance and behaviour, body weights, Cesarean section observations, fetal morphology observations.
- Ovaries and uterine content:
- Immediately following sacrifice, the uterus was excised and weighed prior removal of the fetuses. The umber and location of viable and nonviable fetuses, early and late resorptions and number of total inplantations and corpora lutea were recorded.
- Fetal examinations:
- All fetuses were individually weighed and examined for external malformations and variations, including palate and eyes. Approximaetly one half of the fetuses were used for visceral examinations and the other for skeletal examinations.
- Statistics:
- Male and female sex distribution and the number of litters with malformations were compared using the Chi-square test criterion, Fisher's exact probability test; number of early and late resorptions and postimplantation loss were compared by the Mann-Whitney U-test; the mean number of viable fetuses, total implantations, corpora lutea and mean fetal body weights were compared by anaylsis of variance (one-way classification).
- Historical control data:
- Yes.
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Due to the early deaths of 5 rats and due to signs of excessive maternal toxicity and weight loss in the remaining animals, the rats in the 900 mg/kg7day dosage group were sacrificed and discarded.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Due to the early deaths of 5 rats and due to signs of excessive maternal toxicity and weight loss in the remaining animals, the rats in the 900 mg/kg7day dosage group were sacrificed and discarded.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Due to the early deaths of 5 rats and due to signs of excessive maternal toxicity and weight loss in the remaining animals, the rats in the 900 mg/kg7day dosage group were sacrificed and discarded. A severe decrease in in mean maternal body weight occurred in the 500 mg/kg/day group and a slight to moderate decrease in mean maternal body weight was noted in the 300 mg/kg/day dosage group during the treatment period.
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- There were no remarkable necropsy findings in those females surviving to the scheduled sacrifice with the exception of one non-gravid rat with hdyrometra. in the 300 mg/kg/day dosage group.
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- no effects observed
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Other effects:
- no effects observed
Effect levels (maternal animals)
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 100 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Dose descriptor:
- LOAEL
- Effect level:
- 300 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- a slight decrese in mean fetal body weight was observed in the 100 and 300 mg/kg/day dosage groups when compared to the control group, with a statistical significant decrease in the 500 mg/kg/day dosage group.
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- Changes in postnatal survival:
- no effects observed
- Description (incidence and severity):
- There were no meaningful differences in the mean numbers of corpora lutea, total implantations, postimplantation loss, vialble fetuses or the fetal sex distribution in rats in any of the treated groups when compared to the control group.
- External malformations:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in the number of litters with malformations in any of the treated groups when compared to the control group.
- Skeletal malformations:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in the number of litters with malformations in any of the treated groups when compared to the control group.
- Visceral malformations:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences in the number of litters with malformations in any of the treated groups when compared to the control group.
- Description (incidence and severity):
- a very slight increase in the number of fetuses and litters with malformations was noted in the 500 mg/kg/day dosage group when compared to the control group. This increase was due primarily to 3 fetuses, each from a different litter, with a thread-like tail and a smal anus. The only malformed fetus in the 100 mg/kg/day dosage group also had a thread-like tail and a small anus.
there were no biologically meaningful differences or dose-related trends in the number of fetuses or litters with genetic and developmental variations in any treated group when compared to the control group. - Details on embryotoxic / teratogenic effects:
- treatment with Santocure did not produce a teratogenic response when administered to pregant Charles River COBS CD rats at a dosage level of 500 mg/kg/day or less.
Effect levels (fetuses)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 300 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: fetotoxicity
- Key result
- Dose descriptor:
- LOEL
- Effect level:
- 500 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: fetotoxicity
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 500 mg/kg bw/day
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
Any other information on results incl. tables
Maternal toxicity
900 mg/kg bw/day:
Appearance and behavior: Matting and yellow or red staining of the anogenital region were observed in 23 of 25 rats in the 900 mg/kg bw/day group. Red and chalky urine, a severe red nasal discharge, mucoid ocular discharge, soft stool or hair loss were noted on many rats.
Mortality: 5/25 rats died between gestation days 10 and 12, three of these showing signs of convulsions prior to death. Observations at necropsy on these five rats included: two rats with mucoid ocular discharge and hyperemic bladder mucosa or cecum mucosa; one with slightly congested brain vessels; two with congested lungs; one with mucoid contents in the small intestine and two with a severe, red nasal discharge. Pneumonia was considered a cause of death for 1 dam. A cause of death could not be determined for the remaining animals that died. The remaining 20 rats in the 900 mg/kg bw dosage group were sacrificied between gestation days 11 and 14 due to excessive maternal toxicity.
Body weight gain: serve decreased prior to sacrifice
500 mg/kg bw/day:
mortality: 1/25 (one animal died on gestation day 9. Observations at necropsy revealed a congested thymus and black, fluid contents in the stomach. (No cause of death could be determined for this female).
Matting and/or staining of the vantral surface or anogenital region (noted also in the control (2/25) but with the greatest incidence occuring in the 300 and 500 mg/kg bw/day groups (17/25 rats), hair loss occured in all treatment groups but most frequently at 500 mg/kg bw/day
Body weight gain: serve decrease during the treatment period, slightly reduced body weight gain folowing the treatment period and severely reduced adjusted body weights on gestation day 20
Cesaren section observations: no biologically relevant differences in postimplantation loss or the fetal sex distribution compared to control; however statistically significant decrease in the mean number of corpora lutea, mean number of total implantations and viable fetuses. These findings were considered as not biologically relevant since implantation occurred before test article administration began and the values were within the range established in the historical control data.
300 mg/kg bw/day:
survival: 100 %
Matting and/or staining of the vantral surface or anogenital region (noted also in the control (2/25) but with the greatest incidence occuring in the 300 and 500 mg/kg bw/day groups (12/25 rats)
Necropsy: there were no remarkable necropsy findings in those females surviving to the scheduled sacrifice, with one exception (1/25 non- gravid rats with hydrometra)
Body weight gain: a slight to moderate decrease during the treatment period; adjusted body weights on gestation day 20 were comparable to control
Cesaren section observations: no biologically relevant differences in the mean number of corpora lutea, total implantations, postimplantation loss or viable fetuses or compared to control; however statistically significant differences in the fetal sex distribution; however was attributed to random occurence and was not considered compound relevant.
100 mg/kg bw/day:
Survival: 100 %
No meaningful difference in the appearance or behavior of rats of the 100 mg/kg bw/day group compared to control
Matting and/or staining of the vantral surface or anogenital region (2/25; control 2/25)
Necropsy: there were no remarkable necropsy findings
Body weight gain: no effects
Cesaren section observations: no biologically relevant differences in the mean number of corpora lutea, total implantations, postimplantation loss, viable fetuses or the fetal sex distribution compared to control
Fetal toxicity:
500 mg/kg bw/day:
Statistically significant decrease in mean fetal body weight; these findings were considered as biologically relevant (values were less than of both control groups and historical control data)
Fetal morphological observations:
There were no statistically significant differences in the number of litters with malformation, however a very slight increase in the number of fetuses and litters with malformation was noted; due primarly to 3 fetuses, each from a different litter, with a thread-like tail and a small anus.
300 mg/kg bw/day:
Slight decrease in mean fetal body weight
Fetal morphological observations:
There were no statistically significant differences in the number of litters with malformation
100 mg/kg bw/day:
Slight decrease in mean fetal body weight
Fetal morphological observations:
There were no statistically significant differences in the number of litters with malformation, however 1 fetus had a thread-like tail and a small anus
Remarks:
There were no biologically relevant differences or dose-related trends in the number of fetuses or litters with genetic and developmental variations in any treated group when compared to control group. The occurence of fetuses with a thred-like tail and small anus has previously been observed in litters of control animals in this laboratory. The author concluded that the increase in frequency of fetuses with a thred-like tail and small anus reported in the study may be due to an increase incidence of genetic expression of this condition among female rats used in this study and occurred at a level which exhibited frank materal toxicity.
Applicant's summary and conclusion
- Conclusions:
- The NOAEL derived from this study for maternal toxicity is 100 mg/kg bw and day and is based on a decrease in mean body weight gain. The NOAEL for the offspring is 300 mg/kg bw and day and is based on a decrease mean foetal body weight.
- Executive summary:
In a guideline-consistent developmental toxicity study (Monsanto 1981) which was performed with Charles River COBS CD rats, groups of 25 pregnant females were treated by gavage with CBS at dose levels of 100, 300, 500, and 900 mg/kg bw and day during gestation day 6 to 15. The control group received corn oil. Due to excessive toxicity and death the 900 mg/kg bw and day dose group had to be ceased before end of the study. One maternal death and severe decrease in mean maternal body weight gain and adjusted body weight on gestation day 29 were observed at the 500 mg/kg dose level. A slight to moderate decrease in mean maternal body weight gain was noted in the 300 mg/kg dose group. Hair-loss was noted in all groups, most frequently in the 500 mg/kg dose group. There were no dose-dependent and biologically meaningful effects on mean numbers of corpora lutea, total implantations, post-implantation loss, viable foetuses, or foetal sex distribution in any of the treated groups when compared to controls. There were a very slight increase in the number of foetuses and litters with malformations in the 500 mg/kg dose group due to primarily to three foetuses, each from a different litter, with a thread-like tail and small anus. However, overall, there were no statistically significant differences in the number of litters with malformations in any of the treated groups when compared to the control groups. Further effects observed in the offspring were related to foetal body weight. A slight decrease in mean foetal body weight was observed in the 100 and 300 mg/kg dose group which was statistically significant different from controls for the 500 mg/kg bw and day dose group. The NOAEL derived from this study for maternal toxicity is 100 mg/kg bw and day and is based on a decrease in mean body weight gain. The NOAEL for the offspring is 300 mg/kg bw and day and is based on a decrease mean foetal body weight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.